JPWO2020172440A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020172440A5 JPWO2020172440A5 JP2021548701A JP2021548701A JPWO2020172440A5 JP WO2020172440 A5 JPWO2020172440 A5 JP WO2020172440A5 JP 2021548701 A JP2021548701 A JP 2021548701A JP 2021548701 A JP2021548701 A JP 2021548701A JP WO2020172440 A5 JPWO2020172440 A5 JP WO2020172440A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- scfv
- seq
- baff
- igg4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 16
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 16
- 150000001413 amino acids Chemical class 0.000 claims 11
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 10
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 230000008685 targeting Effects 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808222P | 2019-02-20 | 2019-02-20 | |
| US62/808,222 | 2019-02-20 | ||
| PCT/US2020/019082 WO2020172440A1 (en) | 2019-02-20 | 2020-02-20 | Baff-r/cd19 targeted chimeric antigen receptor-modified t cells and use thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022521240A JP2022521240A (ja) | 2022-04-06 |
| JPWO2020172440A5 true JPWO2020172440A5 (https=) | 2023-02-13 |
| JP2022521240A5 JP2022521240A5 (https=) | 2023-02-13 |
| JP7593646B2 JP7593646B2 (ja) | 2024-12-03 |
Family
ID=69845600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548701A Active JP7593646B2 (ja) | 2019-02-20 | 2020-02-20 | Ｂａｆｆ－ｒ／ｃｄ１９を標的としたキメラ抗原受容体修飾ｔ細胞とその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12545714B2 (https=) |
| EP (1) | EP3927738A1 (https=) |
| JP (1) | JP7593646B2 (https=) |
| KR (1) | KR20210129125A (https=) |
| CN (1) | CN113874391B (https=) |
| WO (1) | WO2020172440A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020132291A1 (en) * | 2018-12-19 | 2020-06-25 | City Of Hope | Baff-r bispecific t-cell engager antibody |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2021163989A1 (en) * | 2020-02-21 | 2021-08-26 | Yinnuolai Biotech Ltd. | Anti-baff receptor antibodies and uses thereof |
| EP4271817A2 (en) | 2020-12-30 | 2023-11-08 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| US20250319130A1 (en) * | 2022-06-01 | 2025-10-16 | Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute | Recombinant receptors binding b cell activation factor receptor and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| DE102014105472B4 (de) | 2014-04-16 | 2016-03-17 | Sartorius Stedim Biotech Gmbh | Misch- und Auftauvorrichtung |
| KR20160145802A (ko) | 2014-04-23 | 2016-12-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법 |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| US10738116B2 (en) | 2015-03-19 | 2020-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-CD22-anti-CD19 chimeric antigen receptors |
| WO2017027291A1 (en) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| KR20250084978A (ko) * | 2016-06-06 | 2025-06-11 | 시티 오브 호프 | Baff-r 표적 키메라 항원 수용체-변형된 t 세포 및 그 용도 |
| CN116041514A (zh) | 2016-06-06 | 2023-05-02 | 希望之城 | Baff-r抗体及其用途 |
| CN108728459B (zh) | 2017-04-24 | 2023-08-04 | 上海恒润达生生物科技股份有限公司 | 靶向cd19的嵌合抗原受体并联合表达il-15的方法和用途 |
| AU2018269194B2 (en) | 2017-05-15 | 2025-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
| CA3287539A1 (en) | 2017-06-21 | 2026-03-02 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
-
2020
- 2020-02-20 KR KR1020217029730A patent/KR20210129125A/ko active Pending
- 2020-02-20 WO PCT/US2020/019082 patent/WO2020172440A1/en not_active Ceased
- 2020-02-20 CN CN202080028641.1A patent/CN113874391B/zh active Active
- 2020-02-20 JP JP2021548701A patent/JP7593646B2/ja active Active
- 2020-02-20 EP EP20712162.5A patent/EP3927738A1/en active Pending
- 2020-02-20 US US17/432,283 patent/US12545714B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513829A5 (https=) | ||
| JP2023139070A5 (https=) | ||
| JP2020010699A5 (https=) | ||
| JP2022113880A5 (https=) | ||
| FI3823665T3 (fi) | BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä | |
| IL264144B1 (en) | Antibody 18a2 against claudin and its use | |
| JP2021511807A5 (https=) | ||
| JP2023071892A (ja) | Ｃｄ２０抗原を標的とするキメラ抗原受容体の構築およびその遺伝子改変ｔ細胞の活性同定 | |
| JP2019537433A5 (https=) | ||
| JP2021525524A5 (https=) | ||
| JP2016514457A5 (https=) | ||
| IL317912A (en) | A combined chimeric antigen receptor targeting CD19 and CD20 and its applications | |
| JP2019536452A5 (https=) | ||
| TW202246330A (zh) | 改良的雙特異性多肽分子 | |
| JP2022501043A5 (https=) | ||
| JP2017524367A5 (https=) | ||
| CA3032581A1 (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| JP2018515123A5 (https=) | ||
| JP2020513754A5 (https=) | ||
| JP2025081512A5 (https=) | ||
| JP2021500881A5 (https=) | ||
| RU2015144332A (ru) | Лечение рака с помощью гуманизированного анти-cd19 химерного антигенного рецептора | |
| RU2015140624A (ru) | Т-клетки, перенацеленные в отношении cd123-специфичного химерного антигенного рецептора, и способы их применения | |
| JP2021526844A5 (https=) | ||
| CN104203981A (zh) | 双特异性抗体分子 |